Luis Forti, MD
Internal Medicine · Bayamon, PRNPI 1205923505
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 38.5% of the total. Reporting peaked in 2021 at $1,721 and has fallen 65.2% since, to $598 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Boehringer Ingelheim$1K
- Johnson & Johnson$571
- Novo Nordisk$523
- Eli Lilly Export S.A. Puerto Rico Branch$470
- Bayer Puerto Rico Inc.$382
- plus $2K from 17 others
What the payments were for
- Food & beverage$7,80298%
- Education$1091%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 141 | $3,068 |
| Boehringer Ingelheim | 58 | $1,318 |
| Johnson & Johnson | 20 | $571 |
| Novo Nordisk | 25 | $523 |
| Eli Lilly Export S.A. Puerto Rico Branch | 21 | $470 |
| Bayer Puerto Rico Inc. | 19 | $382 |
| Bayer | 14 | $319 |
| Amgen | 11 | $219 |
| Merck | 11 | $208 |
| Sanofi-aventis U.S. LLC | 8 | $174 |
| PBG Puerto Rico LLC | 8 | $149 |
| GSK | 4 | $93 |
| E.r. Squibb & Sons, L.L.C. | 5 | $89 |
| Dexcom, Inc. | 4 | $82 |
| Mannkind Corporation | 1 | $59 |
| AbbVie(2 entities) | 2 | $46 |
| Novartis | 2 | $45 |
| Abbott | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Exact Sciences | 1 | $25 |
| Boston Scientific | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Pfizer Pharmaceuticals LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,970 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 327 | $281,418 |
| TrulicityDulaglutide | 150 | $189,455 |
| XareltoRivaroxaban | 182 | $186,375 |
| JardianceEmpagliflozin | 199 | $177,148 |
| EliquisApixaban | 181 | $168,349 |
| Xigduo XrDapaglifloz Propaned/Metformin | 120 | $118,314 |
| SynthroidLevothyroxine Sodium | 1,273 | $110,223 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 112 | $86,666 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 68 | $64,729 |
| OzempicSemaglutide | 56 | $64,456 |
| GlyxambiEmpagliflozin/Linagliptin | 69 | $60,298 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $54,638 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $51,663 |
| JanuviaSitagliptin Phosphate | 41 | $28,750 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $28,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Glyxambi, Tradjenta | $1,318 | $437,115490 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $3,068 | $323,125381 claims |
| Johnson & JohnsonXarelto | $571 | $186,375182 claims |
| AbbVieSynthroid, Linzess | $46 | $127,7661,305 claims |
| MerckJanuvia, Janumet, Janumet Xr | $208 | $84,658100 claims |
| Novo NordiskOzempic, Rybelsus | $523 | $75,26667 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $93 | $71,704122 claims |
| NovartisEntresto | $45 | $22,38913 claims |
| Sanofi-aventis U.S. LLCLantus | $174 | $14,933170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Bayamon
- Sixto MedinaBayamon$15K
- Graciela Latalladi OrtegaBayamon$11K
- Pedro Roman EyxarchBayamon$9K
- Neisa Torres ReyesBayamon$8K
- Carlos AcostaBayamon$7K
- Jose Aviles MunozBayamon$6K
- Steven CruzBayamon$6K
- Lionel Velez MontijoBayamon$6K
- Wanda Beltran VirellaBayamon$5K
- Nelson VallejoLas Piedras$621K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.